Martin Perez-Santos, Maricruz Anaya-Ruiz, Donaciano Flores-Robles, Alejandro Millán-Vega, Pavel Sierra-Martínez
{"title":"Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma.","authors":"Martin Perez-Santos, Maricruz Anaya-Ruiz, Donaciano Flores-Robles, Alejandro Millán-Vega, Pavel Sierra-Martínez","doi":"10.1080/20468954.2025.2535944","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Since CD38 is a protein expressed at high levels in multiple myeloma cells, it is an ideal target for antibody design for treatment.</p><p><strong>Areas covered: </strong>Patent US11905332, which describes two anti-CD38/CD28 bispecific antibodies (bsAb6031 and bsAb7945) with the potential for the treatment of multiple myeloma, was evaluated. The results described in the patent show that the anti-CD38/CD28 bispecific antibodies caused elevated <i>in vitro</i> cytotoxicity in tumor cells through increased proliferation of CD4+ and CD8+ cells, and the release of IFN-γ, IL-2, and TNF-α, as well as efficacy in a mouse model of multiple myeloma.</p><p><strong>Expert opinion: </strong>Anti-CD38/CD28 bispecific antibodies have the potential to be used alone or in combination with other antibodies, including anti-BCMA/CD3 antibodies, for the treatment of multiple myeloma.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-6"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20468954.2025.2535944","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Since CD38 is a protein expressed at high levels in multiple myeloma cells, it is an ideal target for antibody design for treatment.
Areas covered: Patent US11905332, which describes two anti-CD38/CD28 bispecific antibodies (bsAb6031 and bsAb7945) with the potential for the treatment of multiple myeloma, was evaluated. The results described in the patent show that the anti-CD38/CD28 bispecific antibodies caused elevated in vitro cytotoxicity in tumor cells through increased proliferation of CD4+ and CD8+ cells, and the release of IFN-γ, IL-2, and TNF-α, as well as efficacy in a mouse model of multiple myeloma.
Expert opinion: Anti-CD38/CD28 bispecific antibodies have the potential to be used alone or in combination with other antibodies, including anti-BCMA/CD3 antibodies, for the treatment of multiple myeloma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
